Member Info for Darwen68

Tree shake ?

Sycamore gap comes to mind.

Absolutely no point.

You'll just get the same response as you did when people contacted the board,broker,fca etc on the relisting matter.

The response will be,things are being worked on,we can't tell you what and wait for information to be released via an RNS.

It's about opinions.

Without them there would be no point in a discussion board.

We all want the same result,but we differ about the journey there.

Pingu.

I bought into Hemo in Nov 2017, and have held ever since.Since then this board has talked about transformational years every year.

Every year in the annual accounts and overview the progress have always been met with delays - be it research,funding or partnering let downs

I don't doubt Vlad is a good scientist,but as a business leader he is left wavering.For the good of the science and the shareprice the way forward is partnerships than can move things forward at pace with scale and funding.

Vlad talks about partnerships,but I believe he is to egotistical to let anything occur.

The only real "FACT" we know is that Vlad doesn't/can't/won't keep to timelines.

JHFH.

It's blue and?................................there must be a leak,IND must be complete,RNS due by end of day if not soon,the US must know something :- wait till 2:30 when wall street opens,CBR/Car-t imminent,vlad has tweeted a happy face,prevail has maybe bought 10% at 12p.

Both sides of the argument is tedious.

The CX300 could become a workable analyser,it will enter a crowded field and will still need to overcome many regulatory and accreditation stages.

BRH has been promising much from paraytec,phasefocus and kirkstall for a number of years and as yet none have added any substantial value to the shareprice.

Last week I posed the question,that apart from the P2F dividend what has TB and BRH actually invested in that has produced a saleable asset? - there were no replies.

After this mornings RNS it looks like phasefocus is the best positioned asset,but in reality it is a share for the 20% traders for the foreseeable future.

Kicked further into the long grass.

More analytes being put into proof of concept whilst none being proved up.

There will be no firm interest in an analyser at this early stage - and why would there be.

What you have to remember Oldblue is that timelines are irrelevant when it comes to pathfinder.Everything is late,renegotiated and detail is vague.

CP13.

1)your comment about commercialisation of CX300 may be true,however from 70+ interested parties we still have no signs of sale progress 2 or 3 years on.

2)companies sold at a peak ??.

BRH sold/transfered pharm2farm in a covid frenzy,BRH shareholders were fortunate when you see how P2F has performed,or as some would say disintegrated.

I would be grateful if you could point out other small companies BRH had invested in bringing their ideas to commercialisation and subsequently sold for the benefit BRH shareholders.You can't use the words paraytec,kirkstall,phasefocus,velocity aukett.

Putting things into perspective,BRH now at a level it was about 2-3 weeks ago.

Blue is good,but it is still in a hole.

You won't get away with the title "drift"

You will bring on the wrath from the brigade that believe their next pooh will come out with glitter on it.

Surveillance testing will be ramped up, as the winter predicted increase in infection brings added pressure onto the health system.

Presently the number of hospitalisations with positive results,genomic testing,care home testing and anecdotal evidence is how they are monitoring the variants.

Alas,it is not as simple as plonking a CX300 in a monitoring setting,many many hurdles to overcome before that happens. - including any interested parties,regulatory bodies and standards,finance and logistics.

Burgh Island and hotel featured on "Whitehouse and Mortimer gone fishing".

Looked very pleasant indeed.

Brighton.

You say "DYOR and due dilligence"

Prevail Partners have invested in hemogenyx.

Prevail therapeutics is owned by Eli Lilley.

Separate entities.

The thrust of the argument of a future 10p share price is not to be denied,hopefully more partnerships and/or investors may develop.

Barber.

Eli Lillly own Prevail Therapeutics.

Prevail partners have invested in hemogenyx

Same as it was for relisting.

It's just a waiting game.

Why would you expect anything else.

Doubt it will be as simple as profit margin on a total cost.

Whether it is paraytec or a more established medical instrument supplier a lot/most analysers are put in situ on a reagent rental basis and revenue is made on the amount of tests performed,range of tests performed,length of contract, varying service levels and online/phone support.

HH.

3 - I haven't singled out hemogenyx- but as we are on a hemogenyx board I thought that would justify the topic.

2 - The price is drifting down and still below the last placing price.

1- Two good RNS's is a matter of opinion.

Of course your comments are one I would expect from a Vlad Sandler apologist and unhealthy obsession.

It's just normal for Hemo .

It gets a bounce with a sniff of good news and then it drifts down.

Vlad has never managed to release two good news RNS's in quick succession to keep up momentum.

Had hoped for something on cbr or ind,but once again the traders are let back in.